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Abstract
Background: Almost five decades ago, governments around the world adopted the 1961 Single Convention on
Narcotic Drugs which, in addition to addressing the control of illicit narcotics, obligated countries to work towards
universal access to the narcotic drugs necessary to alleviate pain and suffering. Yet, despite the existence of
inexpensive and effective pain relief medicines, tens of millions of people around the world continue to suffer from
moderate to severe pain each year without treatment.
Discussion: Significant barriers to effective pain treatment include: the failure of many governments to put in
place functioning drug supply systems; the failure to enact policies on pain treatment and palliative care; poor
training of healthcare workers; the existence of unnecessarily restrictive drug control regulations and practices; fear
among healthcare workers of legal sanctions for legitimate medical practice; and the inflated cost of pain
treatment. These barriers can be understood not only as a failure to provide essential medicines and relieve
suffering but also as human rights abuses.
Summary: According to international human rights law, countries have to provide pain treatment medications as
part of their core obligations under the right to health; failure to take reasonable steps to ensure that people who
suffer pain have access to adequate pain treatment may result in the violation of the obligation to protect against
cruel, inhuman and degrading treatment.
Background
Chronic pain is a one of the most significant causes of
suffering and disability worldwide, and a common symp-
tom of both cancer and HIV/AIDS. Up to 70% of cancer
patients suffer from pain [1] and, among individuals liv-
ing with HIV/AIDS, wide estimates of pain prevalence
at all stages of infection have been reported [2-18].
While pain prevalence is diminished among individuals
on antiretroviral therapy [16], studies continue to docu-
ment the under-recognition and under-treatment of
pain, even among individuals being treated for HIV
infection [19-22]. Pain treatment is also related to gen-
der, as HIV-infected women with pain are twice as likely
to be under-treated as their male counterparts [21].
Pain has a profound impact on the quality of life and
can have physical, psychological and social conse-
quences. It can lead to reduced mobility and a conse-
quent loss of strength, compromise the immune system
and interfere with a person’s ability to eat, concentrate,
sleep, or interact with others [23]. A World Health
Organization (WHO) study found that people who live
with chronic pain are four times more likely to suffer
from depression or anxiety [24,25]. The physical and
psychological effects of chronic pain influence the
course of disease [26]. Chronic pain can indirectly influ-
ence disease outcomes by reducing treatment adherence.
The WHO Pain Relief Ladder recommends the
administration of different types of pain medications,
depending on the severity of pain, and is the basis of
modern pain management [27]. For mild pain, the
WHO calls for basic pain relievers, usually widely avail-
able without prescription. For mild to moderate pain, it
recommends a combination of basic pain relievers and a
weak opioid, such as codeine. For moderate to severe
pain, the WHO has recognized that strong opioids, such
as morphine, are ‘absolutely necessary’ [28].
The WHO’s recognition of the absolute necessity of
opioid analgesics has reflected the consensus among
health experts for decades. Almost 50 years ago, the
United Nations (UN) member states adopted the 1961
Single Convention on Narcotic Drugs, declaring the med-
ical use of narcotic drugs indispensable for the relief of
pain and mandating an adequate provision of narcotic
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Control Board (INCB), charged with monitoring the
implementation of the UN drug conventions, clarified in
1995 that the Convention ‘establishes a dual drug con-
trol obligation: to ensure adequate availability of narco-
tic drugs, including opiates, for medical and scientific
purposes, while at the same time preventing illicit pro-
duction of, trafficking in and use of such drug’ [30]. The
WHO has included both morphine and codeine in its
Model List of Essential Medicines [31]. Various other
international bodies, such as the UN Economic and
Social Council and the World Health Assembly, have
also called on countries to ensure an adequate availabil-
ity of opioid analgesics [32-35].
Yet, despite this clear consensus that pain treatment
medications should be available, approximately 80% of
the world population has either no, or insufficient, access
to treatment for moderate to severe pain [36]. Millions of
people living with cancer and HIV - including 1 million
end-stage HIV/AIDS patients - suffer from moderate to
severe pain each year without treatment [36].
Pain treatment medications are not evenly distributed
worldwide. Approximately 89% of the total world con-
sumption of morphine occurs in North America and
Europe [37]. Low and middle income countries consume
only 6% of the morphine used worldwide [38], even
though they are home to about half of all cancer
patients [26] and more than 90% of HIV infections [39].
However, inadequate pain management is also prevalent
in developed countries. In the USA, the lack of the
availability of pain medication in pharmacies, misinfor-
mation about addiction on the part of both patients and
providers and fear of criminal sanctions for prescribing
pain medicines are significant limiting factors [40]. Stu-
dies in Western Europe also document an under-estima-
tion of pain severity and under-treatment of pain [17].
This article outlines the common obstacles to the pro-
vision of pain treatment and palliative care and calls for
the reform of laws and policies inhibiting access to pain
treatment worldwide. It also examines access to pain
relief medicine in relation to the obligations of states
under international human rights law. Identifying state
obligations in the context of the HIV/AIDS epidemic
has been a powerful mechanism for mobilizing attention
and compelling response. By developing a human rights
framework related to access to pain relief medicines,
individuals living with HIV, as well as those with cancer
or other causes of pain, can more effectively unite to
demand the accountability of governments to respect,
protect and fulfill their rights.
Discussion
Barriers to access to pain treatment globally include: (1)
the failure of governments to put in place functioning
drug supply systems; (2) the failure to enact policies on
pain treatment and palliative care; (3) poor training of
healthcare workers; (4) the existence of unnecessarily
restrictive drug control regulations and practices; (5)
fear among healthcare workers of legal sanctions for
legitimate medical practice; and (6) the unnecessarily
high cost of pain treatment.
Failure to ensure functioning and effective supply system
Opioid analgesics are controlled medicines and, as such,
their manufacture, distribution and prescription are
strictly regulated. The 1961 Single Convention on Narco-
tic Drugs has created a system for the regulation of sup-
ply and demand, overseen internationally by INCB and
nationally by special drug control agencies. Every year,
countries submit estimates of their need for morphine
and other controlled medications to INCB, which
approves each country’s supply. Cross-border transac-
tions must be authorized and registered by INCB.
As the production, distribution and dispensation of
controlled medicines are under exclusive government
control, governments must also put in place an effective
system of distribution in order to provide healthcare
providers and pharmacies with a continuous and ade-
quate supply of the medications. Yet, many govern-
ments, as a result of resource limitations or lack of
political will, have failed to put in place effective supply
systems for controlled medicines [41]. More fundamen-
tally, there is a lack of a common understanding of opi-
ate pain relief needs and accessibility. A 2006 African
Palliative Care Association survey found that, while drug
control agencies in Kenya, Tanzania and Ethiopia
believed the regulatory system worked well, morphine
consumption in each of these countries was far below
the estimated need and the palliative care providers sur-
veyed identified myriad problems with the regulatory
system [42].
While UN drug conventions require countries to sub-
mit estimates of their need for controlled substances
based on a careful assessment of population needs,
some countries either submit no estimates or submit
only symbolic estimates. For example, the West African
nation of Burkina Faso estimated that it would need 49
g of morphine in 2009 [43]. Based on an estimate for a
terminal cancer or end-stage AIDS patient of a daily
need for 70 mg of morphine for an average of 90 days,
this amount would be sufficient for about eight patients.
Even in countries that estimate a need for considerably
greater absolute quantities of morphine, population
needs are vastly underestimated (Table 1).
Without an effective distribution system, sufficient
supply does not ensure accessibility. As controlled medi-
cations may only be transferred between parties that
have been authorized under national law, governments
must ensure that a sufficient number of pharmacies are
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procuring, stocking and dispensing it are practical.
Yet, in some cases, government regulations allow only
a few institutions to stock the medication, sharply limit-
ing accessibility [42]. In other countries, excessively bur-
densome procedures for procurement, dispensing and
accounting effectively discourage health institutions
from procuring the required morphine [44]. Where hos-
pitals and pharmacies do stock morphine, interruptions
in stock are common [42,45].
Failure to enact palliative care and pain treatment
policies
In 1996, the WHO identified the absence of national
policies on cancer pain relief and palliative care as one
of the reasons that cancer pain is not adequately treated
[46]. In 2000, the organization noted that pain treatment
continued to be a low priority in healthcare systems [28]
and, again, in 2002 it noted that there was a wide gap
between the rhetoric and the reality when integrating
palliative care principles into public health and disease
control programmes [26].
Although the WHO and leading experts on palliative
care have stressed the importance of having a
comprehensive strategy [47], most countries do not have
palliative care and pain treatment policies, either as
stand-alone policies or as part of cancer or HIV/AIDS
control efforts [47,48]. Many countries have even failed
to add oral morphine and other opioid-based medicines
to their list of essential medicines or to issue guidelines
on pain management for healthcare workers [42].
The INCB has recommended that national drug con-
trol laws recognize the indispensible nature of narcotic
drugs for the relief of pain and suffering as well as the
obligation to ensure their availability for medical pur-
poses. However, in 1995 only 48% of the governments
responding to a survey had laws reflecting the former
and 63% the latter [30]. It is not known exactly how
many countries still do not use the relevant language in
their legislation and even recent model laws and regula-
tions on drug control from the UN Office on Drugs and
Crime themselves do not contain these provisions
[49-52] (Appendix 1).
Lack of training for healthcare workers
One of the biggest obstacles to the provision of good
palliative and pain treatment services in many countries
is the lack of training for healthcare workers.
Table 1 Morphine estimates, mortality and pain treatment need.
Country Cancer
deaths
2002
estimate
AIDS
deaths
2005
estimate
No. of individuals
expected to need
pain treatment in
2009
Estimated
total
morphine
need in 2009
(kg)
Estimate of morphine
need provided by
country to INCB for
2009 (kg)
No. of
individuals
estimate is
sufficient for
Percentage of those
needing treatment who
would be covered by
estimate
Countries that estimate almost no need for morphine
Benin 13490 9986 15786 96 0.5 83 0.50%
Senegal 17625 5432 16816 102 0.6 99 0.60%
Rwanda 14196 21956 22335 136 0.8 132 0.60%
Gambia 2395 1430 2631 16 0.18 31 1.20%
Bhutan 727 >10 per
100,000
582 3.5 0.08 14 2.30%
Burkina
Faso
23262 13067 25143 153 0.05 8 0.03%
Eritrea 6240 5959 7972 48 0.075 12 0.15%
Gabon 2071 4457 3886 24 0.088 14 0.40%
Swaziland 1837 17577 10258 62 0.5 82 0.80%
Selected other countries
Egypt 62299 >10 per
100,000
49840 303 10 1646 3%
Philippines 78500 >10 per
100,000
62800 382 31 5103 8%
Kenya 50809 149502 115398 701 30 4938 4%
Russian
Federation
217696 N/A 174157 1058 200 32922 15%
Mexico 92701 6321 77321 470 180 29630 38%
Projection for the numbers of people requiring pain treatment does not include those with acute pain or pain related to non-terminal cancer or HIV and do not
include pain control medications other than morphine. The table is based on an estimate by Foley and others that 80% of terminal cancer patients and 50% of
terminal AIDS patients will require an average of 90 days of pain treatment with 60 mg to 75 mg of morphine per day [16]. Country estimates were obtained
from INCB website [43]; projections for annual cancer and AIDS deaths are based on the most recent cancer and AIDS mortality figures reported by the WHO
[79].
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common among healthcare workers and knowledge of
how to assess and treat pain is often very inadequate.
Some of the most common myths maintain that: treat-
ment with opioids leads to addiction; that pain is neces-
sary because it is enables diagnosis; that pain is
unavoidable; and that pain has negligible consequences.
Each of these myths is inaccurate. Numerous studies
have shown that treatment of pain with opioids very
rarely leads to addiction [28]; most pain can be treated
well [28]; pain is not necessary for diagnosis [23]; and
pain has considerable social, economic and psychologi-
cal consequences as it prevents people who suffer from
it, and often their caregivers, from living a productive
life [23].
Throughout much of the world, including some indus-
trialized countries, ignorance of the use of opioid medi-
cations is the result of a failure to provide healthcare
workers with adequate training in palliative care and
pain management. A survey by the Worldwide Palliative
Care Alliance of healthcare workers in 69 countries in
Latin America, Asia and Africa found that 82% in Latin
America, 71% in Asia and 39% in Africa had not
received any instruction on pain management or opioids
during their undergraduate medical studies [53]. Addi-
tional studies have documented the significant number
of healthcare providers in Africa who report inadequate
opportunities for training in palliative care and pain
treatment [42]. Even in industrialized countries instruc-
tion on palliative care and pain treatment remains a
considerable challenge. A 1999 review found that con-
siderable numbers of healthcare workers had insufficient
factual knowledge about pain management among can-
cer patients in the industrialized countries [54] (Appen-
dix 2).
Excessively restrictive drug control regulations or
enforcement practices
The 1961 the Single Convention on Narcotic Drugs lays
out three minimum criteria that countries must observe
when developing national regulations governing the
handling of opioids. First, individuals must be author-
ized to dispense opioids by their professional license to
practice or be specially licensed to do so. Secondly,
movement of opioids may only occur between institu-
tions or individuals so authorized under national law.
Finally, a medical prescription is required before opioids
may be dispensed to a patient. Governments may, under
the Convention, impose additional requirements if
deemed necessary [29].
However, many countries have regulations that go well
beyond these restrictions, creating complex procedures
for procurement, stocking and dispensing of controlled
medications, including: restrictive licensing requirements
for health care providers prescribing medicines;
cumbersome dispensing procedures; and limitations on
the formulation and quantity of medicine that can be
prescribed [55]. In some cases, drug control authorities
or health systems adopt even more restrictive measures
than those required in the formal regulations. Although
the diversion of medical opiods from its proper use is
frequently cited as the explanation for such policies, the
INCB has noted that, in practice, diversion is relatively
rare [56] and the WHO has observed that ‘this right [to
impose additional requireme n t s ]m u s tb ec o n t i n u a l l y
balanced against the responsibility to ensure opioid
availability for medical purposes’ [46].
An example of overly restrictive policies adopted by
many countries is to limit the prescription of narcotic
pain medicines to medical professionals who qualify for
specific licenses. The 1961 the Single Convention on
Narcotic Drugs does not require healthcare workers to
obtain a special license to handle opioids and the WHO
has recommended that ‘physicians, nurses and pharma-
cists should be legally empowered to prescribe, dispense
and administer opioids to patients in accordance with
local needs’ [46]. Yet special licenses are common, and
nurses and pharmacists are rarely able to prescribe pain
medicines. For example, the Worldwide Palliative Care
Alliance reported that, in 2007, in Mongolia, Peru, Hon-
duras, Kyrgyzstan and a state in India only palliative
care specialists and oncologists are authorized to pre-
scribe oral morphine [53]. In Russia, an AIDS doctor
reported that he could not treat a patient who suffered
from severe pain because he was not licensed to pre-
scribe morphine and that those oncologists who are
would not provide treatment because the patient did
not have cancer [57].
Another common obstacle is the special prescription
procedures for opioids - for example the use of specific
prescription forms and the insistence that multiple
copies of the prescription be maintained. The WHO
Expert Committee on Cancer Pain Relief has observed
that these practices often reduce prescription of opioid
pain medicines by 50% or more [46]. In 1995, INCB
found that 65% of countries that participated in its sur-
vey had special prescription procedures [30].
Another special practice is the requirement that pre-
scriptions by healthcare workers be approved by collea-
gues or superiors and that dispensing must be witnessed
by multiple healthcare workers. In Ukraine, for example,
the decision to prescribe morphine has to be made by a
group of at least three doctors, one of whom must be
an oncologist [58]. In South Africa, two nurses must
observe the dispensing of opioids [42].
While the WHO has recommended that ‘decisions
concerning the type of drug to be used, the amount of
the prescription and the duration of therapy are best
made by medical professionals on the basis of the
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regulations imposing limitations on the dose of oral
morphine that can be prescribed per day or the number
of days for which it can be prescribed are common. The
1995 INCB survey found that 40% of countries partici-
p a t i n gs e tam a x i m u ma m o u n to fm o r p h i n et h a tc o u l d
be prescribed at one time to a hospitalized patient and
50% of countries surveyed set limits for patients who
lived at home [30]. Limits for home-based patients were
frequently less than those for hospitalized patients - in
some cases half of the typical daily doses [16]. The sur-
vey also found that 20% of participating countries
imposed a maximum length of time that a hospitalized
patient could receive morphine and 28% had such
restrictions for patients at home. In some cases, pre-
scriptions for morphine could not exceed a week’ss u p -
ply; in some countries this was non-renewable [30].
Although no recent comprehensive overview of coun-
tries that impose these kinds of limitations is available,
they continue to be widespread [53,59].
Fears of legal sanction
Although the INCB has recommended that healthcare
workers be able to provide opiates without unnecessary
fear of legal action for unintended violations which
would inhibit provision or dispensation [60], ambiguity
in regulations, poor communication by drug regulators
to healthcare workers about the rules for handling
opioids, the existence of harsh sanctions (including
mandatory minimum sentences) and, in some countries,
prosecutions of healthcare workers for unintentional
mishandling of opioids, lead to fear among medical pro-
fessionals. Little research has been published that docu-
ments the extent and impact of fears by healthcare
providers on the prescription practice globally. A recent
survey in the USA of criminal and administrative cases
against physicians related to opiod prescription found
an increasing trend in prosecutions which has a chilling
effect on physician practice [61]. Some authors argue
that physicians have an individual obligation to treat
patients for severe pain and should be held accountable
f o raf a i l u r et ot r e a tp a i nv i aac h a r g eo fm e d i c a lm a l -
practice and, in extreme cases, criminal negligence [62].
Cost
Although basic oral morphine is inexpensive [16], cost is
a frequently cited impediment to improving access to
pain treatment and palliative care services, particularly
for low and middle income countries. A 2003 study
found that the average retail cost of a monthly mor-
phine supply ranged from US$10 in India to US$254 in
Argentina [63]. Paradoxically, the study found that med-
ian cost of a month’s supply of morphine was more
than twice as high in low and middle income countries
(US$112) as in industrialized countries (US$53). The
study suggested that a number of factors might explain
the discrepancy: medication subsidies by industrialized
countries; industrialized government regulation of the
price of opioids; taxes, licenses and other costs related
to import of finished product; large overhead of local
production; poorly developed distribution systems; low
demand; and regulatory requirements that drive up cost.
Further, a 2007 report also found that the promotion of
non-generic - and costly - forms of opioid analgesics
has made pain treatment medications unaffordable in
some areas, as inexpensive formulations are withdrawn
when more expensive opioids appear on the market
[64].
A number of countries have successfully sought ways
to create a capacity for the local production of basic
oral morphine, in tablet or liquid form, at low cost. For
example, in India, a small manufacturing unit has been
set up at a hospital that produces low cost immediate
release morphine tablets from morphine powder [64]. In
Uganda, the ministry of health commissioned charitable
procurement and manufacturing facility to produce
morphine solution which could be distributed to hospi-
tals, health centres and palliative care providers [65]. In
Vietnam, a new opioid prescription regulation allows
the ministry of health to mandate state and para-state
pharmaceutical companies to produce oral and injectible
opioids [66]. These examples illustrate the potential for
creating locally manufactured, low-cost oral morphine.
Health as a human right
Health is a fundamental human right enshrined in
numerous international human rights instruments. The
International Covenant on Economic Social and Cultural
Rights (ICESCR) specifiest h a te v e r y o n eh a sar i g h t‘to
the enjoyment of the highest attainable standard of phy-
sical and mental health’ [67]. The Committee on Eco-
nomic, Social and Cultural Rights, the treaty’s
monitoring body, has held that states must make avail-
able and accessible in sufficient quantity ‘functioning
public health and health-care facilities, goods and ser-
vices, as well as programmes’ [68].
As states have different levels of resources, interna-
tional law does not mandate the kind of health care to
be provided and, instead, demands ‘progressive realiza-
tion’. By committing to the international agreements, a
state agrees ‘to take steps... to the maximum of its avail-
able resources’ to achieve the full realization of the right
to health. High income countries will generally have to
provide healthcare services at a higher level than those
with limited resources, but all countries will be expected
to take concrete steps toward increased services.
The Committee on Economic, Social and Cultural
Rights has also held that there are certain core obliga-
tions that are so fundamental that states must fulfill
them. While resource constraints may justify only partial
fulfillment of some aspects of the right to health, the
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under any circumstances whatsoever, justify its non-
compliance with the core obligations...which are nonder-
ogable’. The Committee has identified, among others,
the following core obligations: to ensure the right of
access to health facilities, goods and services on a non-
discriminatory basis, especially for vulnerable or margin-
alized groups; to provide essential drugs, as from time
to time defined under the WHO Action Programme on
Essential Drugs; to ensure the equitable distribution of
all health facilities, goods and services; and to adopt and
implement a national public health strategy and plan of
action, on the basis of epidemiological evidence, addres-
sing the health concerns of the whole population [68].
Pain treatment and the right to health
As morphine and codeine are on the WHO List of
Essential Medicines [31], countries have to provide these
medications as part of their core obligations under the
right to health, regardless of whether or not they have
been included on their domestic essential medicines lists
[68]. Countries must ensure that they are both available
in adequate quantities and physically and financially
accessible for those who need them.
Since manufacturing and distribution of controlled
medicines, such as morphine and codeine, are comple-
tely in government hands, states must put in place an
effective procurement and distribution system and cre-
ate a legal and regulatory framework that enables
healthcare providers in both the public and private sec-
tors to obtain, prescribe and dispense these medications.
Any regulations that arbitrarily impede the procurement
and dispensing of these medications will violate the
right to health. States must adopt and implement a
strategy and plan of action for the roll out of pain treat-
ment and palliative care services. Such a strategy and
plan of action should identify obstacles to improved ser-
vices as well as take steps to eliminate them.
States should also regularly measure progress made in
ensuring the availability and accessibility of pain relief
medications. The requirement of physical accessibility
means that these medications must be ‘within safe phy-
sical reach for all sections of the population, especially
vulnerable or marginalized groups, such as...persons
with HIV/AIDS’ [68]. This means that states must
ensure that a sufficient number of healthcare providers
or pharmacies stock and dispense morphine and codeine
and that an adequate number of healthcare workers are
trained and authorized to prescribe these medications.
Financial accessibility means that, while the right to
health does not require states to offer medications free
of charge, they must be ‘affordable for all’. According to
the Committee, payment for healthcare services must be
based on equity and poorer households should not be
disproportionately burdened by cost [68].
Countries also have an obligation to progressively
implement palliative care services, which, according to
the WHO, must have ‘priority status within public health
and disease control programmes’ [26]. Countries must
ensure an adequate policy and regulatory framework,
develop a plan for the implementation of these services
and take all steps that are reasonable within available
resources to execute the plan. Failure to attach adequate
priority to developing palliative care services within
healthcare services will violate the right to health [55].
Pain treatment and the right to be free from cruel,
inhuman and degrading treatment
The right to be free from torture, cruel, inhuman and
degrading treatment or punishment is also a fundamen-
tal human right that is recognized in numerous interna-
tional human rights instruments [69-75]. This right
creates a positive obligation for states to protect persons
in their jurisdiction from torture, cruel, inhuman and
degrading treatment or punishment. In a letter to the
Chairperson of the 52nd Session of the Commission on
Narcotic Drugs, the UN Special Rapporteur on Torture,
Cruel, Inhuman and Degrading Treatment and Punish-
ment and the UN Special Rapporteur on the Right to
Health noted that governments’ failure to take measures
to ensure the accessibility of pain treatment threatens
this fundamental right [75].
Summary
The lack of pain treatment medicine is both perplexing
and inexcusable. Pain causes terrible suffering yet the
medications to treat it are cheap, safe, effective and gen-
erally straightforward to administer. Furthermore, inter-
national law obliges countries to make adequate pain
medications available. Over the last 20 years, the WHO
and the INCB have repeatedly reminded states of this
obligation. However, little progress has been made and
tens of millions of people continue to suffer - both
directly from untreated pain and from its consequences.
Under international human rights law, governments
must take steps to ensure that people have adequate
access to treatment for their pain. At a minimum, states
must ensure the availability of morphine, the mainstay
medication for the treatment of moderate to severe
pain. Failure to make essential medicines such as mor-
phine available or, more broadly, to take reasonable
steps to make pain management and palliative care ser-
vices accessible to all, results in a violation of the right
to health. In some cases, failure to ensure patients have
access to treatment for severe pain will also give rise to
a violation of the prohibition of cruel, inhuman and
degrading treatment.
T h e r ea r em a n yr e a s o n sf o rt h ee n o r m i t yo ft h eg a p
between pain treatment needs and what is delivered, but
the chief among them is a willingness by many govern-
ments around the world to passively stand by as people
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ignorance of healthcare providers conspire to create a
vicious cycle of under-treatment. As pain treatment and
palliative care are not priorities for the government,
healthcare workers do not receive the necessary training
in order to assess and treat pain. This leads to wide-
spread under-treatment and to a low demand for mor-
phine. Similarly, complex procurement and prescription
regulations, and the threat of harsh punishment for mis-
handling morphine, discourage pharmacies and hospitals
from stocking and healthcare workers from prescribing
it, which again results in low demand. A lack of the
prioritization of opioid pain medicine is not a result of
the low prevalence of pain but of the invisibility of its
sufferers.
To break out of this vicious cycle, individual govern-
ments and the international community must fulfill
their obligations under international human rights law.
Governments must take action to eliminate barriers that
impede the availability of pain treatment medications.
They must develop policies on pain management and
palliative care; introduce instruction for healthcare
workers, including for those already practicing; reform
regulations that unnecessarily impede the accessibility of
pain medications; and take action to ensure their afford-
ability. While this is a considerable task, various coun-
tries, such as Uganda and Vietnam, have shown that
such a comprehensive approach is feasible in low and
middle-income countries. Other nations must learn
from these experiences and work towards the realization
of full access to pain relief medicines.
Appendix 1: Uganda case study
In 1998, Ugandan government officials, representatives
of non-governmental organizations and the WHO
agreed on ways in which pain treatment could be made
available to the population. These steps included: devel-
oping national palliative care, cancer and AIDS pain
relief policies; implementing a training course to com-
plement existing palliative medicine teaching and
increasing the number of skilled providers; developing
new drug regulations: updating the essential drug list;
conducting estimates of the medical need for morphine;
and requests from the drug control authority for an
increased national allowance from the INCB [77].
Following this agreement, Uganda has made consider-
able progress in reducing or eliminating barriers that
have traditionally impeded access to pain treatment
medications. In its 5-year Strategic Health Plan for
2000-2005, the government noted that palliative care
was an essential clinical service for all Ugandans and so
became the first nation in Africa to do so. It also added
liquid morphine to its essential drug list, adopted a new
set of guidelines for the handling of class A drugs for
healthcare practitioners - also a first in Africa - and
authorized the prescribing of morphine by nurses who
have been trained in palliative care. By early 2009, 79
nurses and clinical officers had received training in pain
management and been authorized to prescribe oral mor-
phine, several thousand healthcare workers had attended
a short course on pain and symptom management and
34 out of 56 districts in Uganda had oral morphine
available and in use [65]. Despite this impressive pro-
gress, many challenges remain, including: ensuring the
availability of oral morphine throughout Uganda; keep-
ing it affordable; preventing stockouts; and training all
relevant healthcare workers.
Appendix 2: Vietnam case study
Since 2005, Vietnam has made considerable progress in
expanding access to palliative and pain treatment ser-
vices. A working group on palliative care, including
health officials, physicians and NGOs, conducted a rapid
situation analysis devised to assess the availability of,
and need for, palliative care in Vietnam. This rapid ana-
lysis found severe chronic pain to be common among
cancer and HIV/AIDS patients, while the availability of
opioid analgesics was severely limited, palliative care ser-
vices were not readily available and clinicians lacked
adequate training [78]. The working group recom-
mended that national palliative care guidelines be devel-
oped, a balanced national opioid control policy be
designed, training for healthcare workers be expanded
and that the availability and quality of palliative care ser-
vices be improved.
In 2006, the Ministry of Health issued detailed guide-
lines to practitioners on palliative care and pain man-
agement and, in 2008, it issued new guidelines on
opioid prescription which have eased a number of key
regulatory barriers. The Ministry has also approved a
package of training courses for practicing physicians and
two medical colleges now offer instruction on palliative
care to undergraduate medical and nursing students.
However, only a few hundredh e a l t h c a r ew o r k e r sh a v e
received training so far, understanding of palliative care
among healthcare officials continues to be limited, var-
ious regulatory barriers persist and few pharmacies and
hospitals stock oral morphine.
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